Q-omics provides the consensus-scored ABHD17B profile across patient tissues and cancer cell-line models. ABHD17B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ABHD17B is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, ABHD17B protein abundance shows 25,153 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, THCA, and GBM as cancer lineages where ABHD17B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABHD17B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABHD17B survival associations across molecular data types. ABHD17B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABHD17B RNA expression–survival associations across cancer types. High ABHD17B expression shows unfavorable associations in ACC, MESO and UVM, but favorable associations in KIRC, HNSC and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ABHD17B RNA expression.
This table summarizes ABHD17B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ABHD17B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABHD17B shows lower tumor expression in THCA, KICH and LUAD and higher tumor expression in LIHC, LUSC and ESCA. The THCA box plot shows higher ABHD17B RNA expression in normal versus tumor tissue (log2 FC = −0.998, t-test p < 0.001).
This table shows molecular features associated with ABHD17B in patient tissues and cancer cell lines. In patient samples, ABHD17B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ABHD17B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUAD.
